ZhongSheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 111 million yuan, a decrease of 40.70% compared with the same period last year. The company's total operating revenue was 1 billion yuan, a decrease of 299 million yuan from the same period last year, down 23.03% year-on-year. Net cash inflow from operating activities was 542 million yuan. The latest asset-liability ratio was 17.64%, gross margin was 56.33%, and ROE was 2.78%. Diluted earnings per share were 0.13 yuan, down 40.91% year-on-year.
Guangdong Zhongsheng Pharmaceutical Co LtdNet profit down 40.70% and revenue down 23.03% year-on-year.
